



Issued by Park Square Executive Search

Deciphera Pharmaceuticals Appoints David Brooks, M.D., Ph.D. as Vice President, Clinical Development & Translational Medicine

Deciphera Pharmaceuticals has appointed David Brooks as Vice President, Clinical Development & Translational Medicine. Brooks most recently served as Senior Director Physician, Early Clinical Development at AstraZeneca. Previously, Brooks served at Tesaro, Inc. as Medical Head, Translational Medicine.

Prior positions include: Chief Medical Officer, SVP at Generation Health; Medical Director, Global Clinical Development at Abraxis Bioscience; Medical Director, Clinical Affairs and Translational Medicine at Shire Human Genetic Therapies; and Associate Director, Clinical Oncology & Clinical Molecular Profiling at Merck & Co, Inc.

Brooks received his B.A. in Molecular, Cellular, and Developmental Biology from The University of Colorado; his M.D. from Cornell University Medical College; and his Ph.D. in Molecular Biology from Cornell University Graduate School of Medical Sciences.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.